Evidence map›Paper›PMID 31956346›Full record

ArticleJournal of Cancer2020

Development and validation of a robust multigene signature as an aid to predict early relapse in stage I-III clear cell and papillary renal cell cancer.

Da-Long Cao, Wei-Xing Dai, Yong-Qiang Huang, Lei-Jun Yu, Jun-Long Wu, Guo-Hai Shi, Hai-Liang Zhang, Yao Zhu, Bo Dai, Ding-Wei Ye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Da-Long CaoDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Wei-Xing DaiDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
Yong-Qiang HuangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Lei-Jun YuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jun-Long WuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Guo-Hai ShiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hai-Liang ZhangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Yao ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Bo DaiDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ding-Wei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Fudan University Shanghai Cancer Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BiomarkerEarly relapsemRNA signaturePrognosisRenal cell carcinoma

Identifiers

PMID31956346
PMCPMC6959077
OpenAlexW3006087695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.